Last updated July 22, 2026
Key finding
Mean MRI-PDFF decreased from 15.289 ± 8.72 to 13.28 ± 7.15, P = 0.006.
The study investigated the effects of adding Empagliflozin to standard treatment in patients with Type 2 Diabetes, finding significant reductions in hepatic fat mass and BMI.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The study investigated the effects of adding Empagliflozin to standard treatment in patients with Type 2 Diabetes, finding significant reductions in hepatic fat mass and BMI.
These findings are clinically significant as they suggest that Empagliflozin may be an effective addition to standard diabetes treatment, potentially improving liver health and reducing the risk of complications associated with hepatic steatosis in diabetic patients.
Non-randomized design may introduce bias. Limited generalizability due to specific population characteristics. No significant changes observed in Fib-4 and NAFLD fibrosis scores.
Published in
Publication details and source links for this paper.
Mona AA, Noha AS, Hala AS, Mohammed F, Hend AE. Adding Empagliflozin to Standard Treatment Reduces Hepatic Steatosis in Type 2 Diabetes Patients. Internal and Emergency Medicine. 2025;20(4):1025-1033. doi:10.1007/s11739-025-03902-w
Hepatic fat mass decreased by 1.999 percentage points (P = 0.006).
BMI decreased by 1.83 kg/m² (P < 0.001).
Fasting blood glucose decreased by 26.614 mg/dl (P = 0.017).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Empagliflozin and Alanine Aminotransferase (ALT), BMI, FIB-4 index, and 3 more.
This study contributes evidence to
Primary intervention
Empagliflozin
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
6
Evidence pairs
451
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
Empagliflozin → Alanine Aminotransferase (ALT)
Empagliflozin → Alanine Aminotransferase (ALT)
Empagliflozin → Fasting blood sugar (FBS)
Empagliflozin → Fasting blood sugar (FBS)
Empagliflozin → Percentage change in hepatic fat mass measured by MRI-PDFF
Empagliflozin → Percentage change in hepatic fat mass measured by MRI-PDFF
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and Adipokine and Angiogenic Markers, SGLT2 Inhibitors and Body Mass Index.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
All studies measuring Body Mass Index
Measures Body Mass Index as a key outcome.
All studies on SGLT2 Inhibitors
Contributes to SGLT2 Inhibitors evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
2 results
2 results
2 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
SGLT2 Inhibitors may improve Fasting Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Fasting blood sugar (FBS)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Alanine Aminotransferase (ALT)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors appears to improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
BMI
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
Empagliflozin appears to improve Percentage change in hepatic fat mass measured by MRI-PDFF.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Percentage change in hepatic fat mass measured by MRI-PDFF
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
